Holen Sie sich die Stockscreener-App
1.46
9.03%
-0.145
Handel nachbörslich:
1.47
0.01
+0.68%
Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten
FY2028 EPS Estimates for Compass Therapeutics Cut by Wedbush - Defense World
Leerink Partners Upgrades Compass Therapeutics (NASDAQ:CMPX) to Outperform - Defense World
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from Guggenheim - Defense World
Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint - insights.citeline.com
Compass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink Partnrs - Defense World
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times
Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq
Compass Therapeutics rises on trial win for biliary tract cancer therapy - MSN
Leerink raises Compass Therapeutics stock rating, PT to $6 from $4 - Investing.com
Compass Therapeutics And 2 More Compelling Penny Stocks - Yahoo Finance
Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush - Defense World
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing - GlobeNewswire
Compass Therapeutics price target raised to $11 from $10 at Stifel - MSN
Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Benzinga
Clinical Breakthrough Propels Compass Therapeutics (CMPX) Stock Higher - Stocks Telegraph
Compass Therapeutics Reports Positive Phase 2/3 Trial Results For Tovecimig - Nasdaq
Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed - Endpoints News
Compass Therapeutics stock down amid trial win (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms - TradingView
Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate - MarketScreener
Compass Therapeutics stock rises on trial win (CMPX:NASDAQ) - Seeking Alpha
Compass Therapeutics Reports Positive Phase 2/3 Trial Results - TipRanks
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - The Manila Times
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Compass Therapeutics to Host Webcast Highlighting Top-Line - GlobeNewswire
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - The Manila Times
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns - simplywall.st
Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5? - Yahoo
Connor Clark & Lunn Investment Management Ltd. Trims Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
[Top 3] Best Biotech Penny Stocks to Buy in 2025Finbold - Finbold - Finance in Bold
10 Hot Biotech Stocks Under $5 - Insider Monkey
With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest - Yahoo Canada Finance
Gallbladder Neoplasms Treatment Market Size in the 7MM - openPR
Compass Therapeutics (CMPX) Projected to Post Earnings on Thursday - Defense World
Rubicon Technology (NASDAQ:RBCN) Now Covered by Analysts at StockNews.com - Defense World
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to Hold - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review - Defense World
Research Analysts Issue Forecasts for CMPX Q1 Earnings - Defense World
Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
D. Boral Capital Reiterates "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics shares rise on pipeline progress By Investing.com - Investing.com Canada
Compass Therapeutics shares rise on pipeline progress - Investing.com
Compass Therapeutics Reports 2024 Financial Results - TipRanks
Compass Therapeutics reports Q4 EPS (11c), consensus (9c) - TipRanks
Compass Therapeutics, Inc. SEC 10-K Report - TradingView
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Guggenheim - MarketBeat
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):